Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck Launches Rexulti In Europe, Phase II LU AF11167 Trial In Schizophrenia

Executive Summary

Danish CNS specialist begins Rexulti roll-out in Europe and proof-of-concept study of its early pipeline candidate Lu AF11167.

Advertisement

Related Content

The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic
Generic Blow Looms For Lundbeck
Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates
Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel